{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:05:09Z","timestamp":1793135109229,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National TCM Comprehensive Reform Demonstration Zone S&T Co-construction Initiative","award":["GZY-KJS-ZJ-2025-017"],"award-info":[{"award-number":["GZY-KJS-ZJ-2025-017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00109-025-02614-0","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:43:22Z","timestamp":1766155402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The promising arsenal of ferroptosis inducers in bladder cancer"],"prefix":"10.1007","volume":"104","author":[{"given":"Nan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5048-3262","authenticated-orcid":false,"given":"Xiaodong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"3","key":"2614_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2614_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2011.09.004","volume":"61","author":"X-D Jin","year":"2011","unstructured":"Jin X-D, Roethlisberger S, Burkhard FC, Birkhaeuser F, Thoeny HC, Studer UE (2011) Long-term renal function after urinary diversion by ileal conduit or orthotopic ileal bladder substitution. Eur Urol 61(3):491\u2013497","journal-title":"Eur Urol"},{"issue":"1","key":"2614_CR3","volume":"12","author":"D-C Feng","year":"2025","unstructured":"Feng D-C, Li D-X, Wu R-C, Wang J, Xiao Y-H, Yoo KH et al (2025) Global burden and cross-country inequalities in urinary tumors from 1990 to 2021 and predicted incidence changes to 2046. Mil Med Res 12(1):12","journal-title":"Mil Med Res"},{"key":"2614_CR4","doi-asserted-by":"publisher","unstructured":"Esteban-Villarrubia J, Torres-Jim\u00e9nez J, Bueno-Bravo C, Garc\u00eda-Mondaray R, Subiela JD, Gajate P (2023) Current and future landscape of perioperative treatment for muscle-invasive bladder cancer. Cancers (Basel) 15(3). https:\/\/doi.org\/10.3390\/cancers15030566","DOI":"10.3390\/cancers15030566"},{"issue":"15","key":"2614_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70088","volume":"13","author":"A Mendoza-Valderrey","year":"2024","unstructured":"Mendoza-Valderrey A, Choe J, Kessler DM, Jimenez G, Li X, Kolker S et al (2024) Impact of intra-tumoral immunity on predicting response and survival after neoadjuvant cisplatin-based chemotherapy in patients with muscle invasive bladder cancer. Cancer Med 13(15):e70088","journal-title":"Cancer Med"},{"issue":"1","key":"2614_CR6","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1038\/s41467-024-48480-1","volume":"15","author":"W Beckabir","year":"2024","unstructured":"Beckabir W, Zhou M, Lee JS, Vensko SP, Woodcock MG, Wang H-H et al (2024) Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nat Commun 15(1):4448","journal-title":"Nat Commun"},{"key":"2614_CR7","doi-asserted-by":"publisher","first-page":"e2300274","DOI":"10.1200\/PO.23.00274","volume":"8","author":"AT Lenis","year":"2024","unstructured":"Lenis AT, Whiting K, Ravichandran V, Tallman JE, Alam SM, Chu CE et al (2024) Natural history and genomic landscape of chemotherapy-resistant muscle-invasive bladder cancer. JCO Precis Oncol 8:e2300274","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"2614_CR8","doi-asserted-by":"publisher","first-page":"8201","DOI":"10.3390\/cimb45100517","volume":"45","author":"Z Shan","year":"2023","unstructured":"Shan Z, Tang W, Shi Z, Shan T (2023) Ferroptosis: an emerging target for bladder cancer therapy. Curr Issues Mol Biol 45(10):8201\u20138214","journal-title":"Curr Issues Mol Biol"},{"issue":"5","key":"2614_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41419-024-06766-8","volume":"15","author":"Y Vinik","year":"2024","unstructured":"Vinik Y, Lev S (2024) A snapshot into the transcriptomic landscape of apoptosis and ferroptosis in cancer. Cell Death Dis 15(5):371","journal-title":"Cell Death Dis"},{"key":"2614_CR10","doi-asserted-by":"publisher","first-page":"670384","DOI":"10.3389\/fgene.2021.670384","volume":"12","author":"F Zhang","year":"2021","unstructured":"Zhang F, Wang X, Bai Y, Hu H, Yang Y, Wang J et al (2021) Development and validation of a hypoxia-related signature for predicting survival outcomes in patients with bladder cancer. Front Genet 12:670384","journal-title":"Front Genet"},{"issue":"1","key":"2614_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12935-021-02264-5","volume":"21","author":"S Zhao","year":"2021","unstructured":"Zhao S, Li P, Wu W, Wang Q, Qian B, Li X et al (2021) Roles of ferroptosis in urologic malignancies. Cancer Cell Int 21(1):676","journal-title":"Cancer Cell Int"},{"key":"2614_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.08.003","author":"Y Ping","year":"2024","unstructured":"Ping Y, Shan J, Qin H, Li F, Qu J, Guo R et al (2024) PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis. Immunity. https:\/\/doi.org\/10.1016\/j.immuni.2024.08.003","journal-title":"Immunity"},{"key":"2614_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ph18081183","author":"B Kielan","year":"2025","unstructured":"Kielan B, Pa\u0142asz A, Krysta K, Krzystanek M (2025) Ferroptosis as a form of cell death-medical importance and pharmacological implications. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph18081183","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"2614_CR14","doi-asserted-by":"publisher","first-page":"e70349","DOI":"10.1002\/mco2.70349","volume":"6","author":"G Shen","year":"2025","unstructured":"Shen G, Liu J, Wang Y, Deng Z, Deng F (2025) Ferroptosis in cancer and inflammatory diseases: mechanisms and therapeutic implications. MedComm 6(9):e70349","journal-title":"MedComm"},{"key":"2614_CR15","doi-asserted-by":"publisher","first-page":"830561","DOI":"10.3389\/fonc.2022.830561","volume":"12","author":"Y Chen","year":"2022","unstructured":"Chen Y, Fan Z, Hu S, Lu C, Xiang Y, Liao S (2022) Ferroptosis: a new strategy for cancer therapy. Front Oncol 12:830561","journal-title":"Front Oncol"},{"issue":"9","key":"2614_CR16","doi-asserted-by":"publisher","first-page":"9129","DOI":"10.1021\/acs.jmedchem.4c02929","volume":"68","author":"CW Parry","year":"2025","unstructured":"Parry CW, Pellicano F, Sch\u00fcttelkopf AW, Beyer KS, Bower J, Bryson A et al (2025) Reversible small molecule multivariant Ras inhibitors display tunable affinity for the active and inactive forms of Ras. J Med Chem 68(9):9129\u20139161","journal-title":"J Med Chem"},{"key":"2614_CR17","doi-asserted-by":"publisher","unstructured":"Tsuruta K, Matsuoka M, Harada S, Enomoto A, Kumagai T, Yasuda S,\u00a0Koumura T, Yamada KI, Imai H\u00a0(2023) Slowly progressive cell death induced by GPx4-deficiency occurs via MEK1\/ERK2 activation as a downstream signal after iron-independent lipid peroxidation. J Clin Biochem Nutr 74(2):97\u2013107. https:\/\/doi.org\/10.3164\/jcbn.23-101","DOI":"10.3164\/jcbn.23-101"},{"key":"2614_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010449","author":"L Rochette","year":"2022","unstructured":"Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C (2022) Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24010449","journal-title":"Int J Mol Sci"},{"issue":"24","key":"2614_CR19","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.2174\/0929867329666220111120924","volume":"29","author":"N Zaffaroni","year":"2022","unstructured":"Zaffaroni N, Beretta GL (2022) Ferroptosis inducers for prostate cancer therapy. Curr Med Chem 29(24):4185\u20134201","journal-title":"Curr Med Chem"},{"issue":"14","key":"2614_CR20","doi-asserted-by":"publisher","first-page":"e70710","DOI":"10.1111\/jcmm.70710","volume":"29","author":"P Li","year":"2025","unstructured":"Li P, Yao S, Qi W, Liu H, Zhang X, Zhou B et al (2025) Identification of FADS2 as a contributor of ferroptosis escape in bladder cancer. J Cell Mol Med 29(14):e70710","journal-title":"J Cell Mol Med"},{"key":"2614_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1428920","volume":"15","author":"Y Cao","year":"2024","unstructured":"Cao Y, Lu C, Beeraka NM, Efetov S, Enikeev M, Fu Y et al (2024) Exploring the relationship between anastasis and mitochondrial ROS-mediated ferroptosis in metastatic chemoresistant cancers: a call for investigation. Front Immunol 15:1428920","journal-title":"Front Immunol"},{"issue":"4","key":"2614_CR22","doi-asserted-by":"publisher","first-page":"e1644","DOI":"10.1002\/wsbm.1644","volume":"16","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zou L, Li X, Guo L, Hu B, Ye H et al (2024) SLC40A1 in iron metabolism, ferroptosis, and disease: a review. WIREs Mechanisms of Disease 16(4):e1644","journal-title":"WIREs Mechanisms of Disease"},{"issue":"1","key":"2614_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13046-022-02288-3","volume":"41","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zheng Q, Yue X, Yuan Z, Ling J, Yuan Y et al (2022) ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation. J Exp Clin Cancer Res 41(1):79","journal-title":"J Exp Clin Cancer Res"},{"key":"2614_CR24","doi-asserted-by":"crossref","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G et al (2020) European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79(1):82-104","DOI":"10.1016\/j.eururo.2020.03.055"},{"issue":"1","key":"2614_CR25","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41420-024-02195-w","volume":"10","author":"W Ma","year":"2024","unstructured":"Ma W, Jiang X, Jia R, Li Y (2024) Mechanisms of ferroptosis and targeted therapeutic approaches in urological malignancies. Cell Death Discov 10(1):432","journal-title":"Cell Death Discov"},{"key":"2614_CR26","doi-asserted-by":"publisher","first-page":"629150","DOI":"10.3389\/fcell.2021.629150","volume":"9","author":"H Wang","year":"2021","unstructured":"Wang H, Lin D, Yu Q, Li Z, Lenahan C, Dong Y et al (2021) A promising future of ferroptosis in tumor therapy. Front Cell Dev Biol 9:629150","journal-title":"Front Cell Dev Biol"},{"issue":"19","key":"2614_CR27","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.21037\/atm-21-1595","volume":"9","author":"J-J Zhang","year":"2021","unstructured":"Zhang J-J, Du J, Kong N, Zhang G-Y, Liu M-Z, Liu C (2021) Mechanisms and pharmacological applications of ferroptosis: a narrative review. Ann Transl Med 9(19):1503","journal-title":"Ann Transl Med"},{"issue":"1","key":"2614_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11596-023-2814-6","volume":"44","author":"W-X An","year":"2023","unstructured":"An W-X, Gupta R, Zhai K, Wang Y-R, Xu W-H, Cui Y (2023) Current and potential roles of ferroptosis in bladder cancer. Curr Med Sci 44(1):51\u201363","journal-title":"Curr Med Sci"},{"issue":"8","key":"2614_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2020","unstructured":"Koppula P, Zhuang L, Gan B (2020) Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12(8):599\u2013620","journal-title":"Protein Cell"},{"issue":"1","key":"2614_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41391-022-00583-w","volume":"26","author":"Y Wang","year":"2022","unstructured":"Wang Y, Ma Y, Jiang K (2022) The role of ferroptosis in prostate cancer: a novel therapeutic strategy. Prostate Cancer Prostatic Dis 26(1):25\u201329","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2614_CR31","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.2147\/DDDT.S472178","volume":"18","author":"Y Luo","year":"2024","unstructured":"Luo Y, Bai XY, Zhang L, Hu QQ, Zhang N, Cheng JZ et al (2024) Ferroptosis in cancer therapy: mechanisms, small molecule inducers, and novel approaches. Drug Des Devel Ther 18:2485\u20132529","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2614_CR32","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1186\/s12885-021-08687-7","volume":"21","author":"Y Liang","year":"2021","unstructured":"Liang Y, Ye F, Xu C, Zou L, Hu Y, Hu J et al (2021) A novel survival model based on a ferroptosis-related gene signature for predicting overall survival in bladder cancer. BMC Cancer 21(1):943","journal-title":"BMC Cancer"},{"key":"2614_CR33","doi-asserted-by":"publisher","first-page":"775506","DOI":"10.3389\/fphar.2021.775506","volume":"12","author":"Y Xiang","year":"2021","unstructured":"Xiang Y, Chen X, Wang W, Zhai L, Sun X, Feng J et al (2021) Natural product erianin inhibits bladder cancer cell growth by inducing ferroptosis via NRF2 inactivation. Front Pharmacol 12:775506","journal-title":"Front Pharmacol"},{"issue":"7","key":"2614_CR34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41419-024-06848-7","volume":"15","author":"Y-N Zheng","year":"2024","unstructured":"Zheng Y-N, Lou S-Y, Lu J, Zheng F-L, Tang Y-M, Zhang E-J et al (2024) Selective PI3K\u03b4 inhibitor TYM-3-98 suppresses AKT\/mTOR\/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer. Cell Death Dis 15(7):474","journal-title":"Cell Death Dis"},{"issue":"3","key":"2614_CR35","doi-asserted-by":"publisher","first-page":"6794","DOI":"10.1080\/21655979.2022.2036909","volume":"13","author":"J Hao","year":"2022","unstructured":"Hao J, Zhang W, Huang Z (2022) Bupivacaine modulates the apoptosis and ferroptosis in bladder cancer via phosphatidylinositol 3-kinase (PI3K)\/AKT pathway. Bioengineered 13(3):6794\u20136806","journal-title":"Bioengineered"},{"issue":"3","key":"2614_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3892\/ol.2022.13421","volume":"24","author":"Y Wang","year":"2022","unstructured":"Wang Y, Shao W, Feng Y, Tang J, Wang Q, Zhang D et al (2022) Prognostic value and potential biological functions of ferroptosis-related gene signature in bladder cancer. Oncol Lett 24(3):301","journal-title":"Oncol Lett"},{"key":"2614_CR37","doi-asserted-by":"publisher","first-page":"115104","DOI":"10.1016\/j.ejmech.2023.115104","volume":"248","author":"H Xiao","year":"2023","unstructured":"Xiao H, Wang G, Zhao M, Shuai W, Ouyang L, Sun Q (2023) Ras superfamily GTPase activating proteins in cancer: potential therapeutic targets? Eur J Med Chem 248:115104","journal-title":"Eur J Med Chem"},{"issue":"7998","key":"2614_CR38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/d41586-024-00080-1","volume":"626","author":"DD Zhang","year":"2024","unstructured":"Zhang DD (2024) Natural inhibitor found for cell death by ferroptosis. Nature 626(7998):269\u2013270","journal-title":"Nature"},{"key":"2614_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11122444","author":"J Lee","year":"2022","unstructured":"Lee J, Roh J-L (2022) SLC7A11 as a gateway of metabolic perturbation and ferroptosis vulnerability in cancer. Antioxidants. https:\/\/doi.org\/10.3390\/antiox11122444","journal-title":"Antioxidants"},{"issue":"4","key":"2614_CR40","doi-asserted-by":"publisher","first-page":"e1054549","DOI":"10.1080\/23723556.2015.1054549","volume":"2","author":"Y Yu","year":"2015","unstructured":"Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT et al (2015) The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol 2(4):e1054549","journal-title":"Mol Cell Oncol"},{"key":"2614_CR41","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/OTT.S254995","volume":"13","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Li Y, Zhang R, Wang F, Wang T, Jiao Y (2020) The role of erastin in ferroptosis and its prospects in cancer therapy. Onco Targets Ther 13:5429\u20135441","journal-title":"Onco Targets Ther"},{"key":"2614_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413335","author":"J Zou","year":"2021","unstructured":"Zou J, Wang L, Tang H, Liu X, Peng F, Peng C (2021) Ferroptosis in non-small cell lung cancer: progression and therapeutic potential on it. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222413335","journal-title":"Int J Mol Sci"},{"issue":"39","key":"2614_CR43","doi-asserted-by":"publisher","first-page":"E771","DOI":"10.1073\/pnas.1106149108","volume":"108","author":"AJ Wolpaw","year":"2011","unstructured":"Wolpaw AJ, Shimada K, Skouta R, Welsch ME, Akavia UD, Pe\u2019er D et al (2011) Modulatory profiling identifies mechanisms of small molecule-induced cell death. Proc Natl Acad Sci U S A 108(39):E771\u2013E780","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2614_CR44","doi-asserted-by":"publisher","first-page":"107915","DOI":"10.1016\/j.phrs.2025.107915","volume":"219","author":"D Lv","year":"2025","unstructured":"Lv D, Shi Y, Kou L, Zhang D, Guo Y, Zhao S (2025) Precision targeting of androgen receptor-ferroptosis crosstalk in prostate cancer: from mechanisms to therapeutic strategies. Pharmacol Res 219:107915","journal-title":"Pharmacol Res"},{"issue":"6","key":"2614_CR45","doi-asserted-by":"publisher","first-page":"e0052221","DOI":"10.1128\/mcb.00522-21","volume":"42","author":"H Wang","year":"2022","unstructured":"Wang H, Wang P, Zhu BT (2022) Mechanism of erastin-induced ferroptosis in MDA-MB-231 human breast cancer cells: evidence for a critical role of protein disulfide isomerase. Mol Cell Biol 42(6):e0052221","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2614_CR46","first-page":"853","volume":"55","author":"M-J Hou","year":"2023","unstructured":"Hou M-J, Wang P, Zhu BT (2023) Biochemical mechanism of erastin-induced ferroptotic cell death in neuronal cells. Acta Biochim Biophys Sin (Shanghai) 55(5):853\u2013865","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"2614_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115844","volume":"261","author":"L Ma","year":"2023","unstructured":"Ma L, Li M, Zhang Y, Liu K (2023) Recent advances of antitumor leading compound erianin: mechanisms of action and structural modification. Eur J Med Chem 261:115844","journal-title":"Eur J Med Chem"},{"issue":"9","key":"2614_CR48","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1007\/s12010-023-04829-8","volume":"196","author":"A Hu","year":"2024","unstructured":"Hu A, Li K (2024) Erianin impedes the proliferation and metastatic migration through suppression of STAT-3 phosphorylation in human esophageal cancer cells. Appl Biochem Biotechnol 196(9):5859\u20135874","journal-title":"Appl Biochem Biotechnol"},{"issue":"7","key":"2614_CR49","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1111\/febs.16382","volume":"290","author":"H Nishizawa","year":"2022","unstructured":"Nishizawa H, Yamanaka M, Igarashi K (2022) Ferroptosis: regulation by competition between NRF2 and BACH1 and propagation of the death signal. FEBS J 290(7):1688\u20131704","journal-title":"FEBS J"},{"key":"2614_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1293980","volume":"15","author":"T Wang","year":"2024","unstructured":"Wang T, Zhou Z, Jiang K, Wang Y, Li P, Wang S (2024) The potential anti-tumor effect of anesthetics on cancer by regulating autophagy. Front Pharmacol 15:1293980","journal-title":"Front Pharmacol"},{"issue":"4","key":"2614_CR51","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2174\/1574892817666220119121204","volume":"17","author":"Z Jin","year":"2022","unstructured":"Jin Z, Zhang W, Liu H, Ding A, Lin Y, Wu S-X et al (2022) Potential therapeutic application of local anesthetics in cancer treatment. Recent Pat Anticancer Drug Discov 17(4):326\u2013342","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"186","key":"2614_CR52","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.24976\/Discov.Med.202436186.139","volume":"36","author":"E Guan","year":"2024","unstructured":"Guan E, Zhang J, Zhou J, Liu Y, Xu N (2024) Local anesthetic bupivacaine inhibits melanoma proliferation and metastasis by targeting PAPSS2. Discov Med 36(186):1499\u20131512","journal-title":"Discov Med"},{"key":"2614_CR53","doi-asserted-by":"publisher","unstructured":"Greco G, Catanzaro E, Fimognari C (2021) Natural products as inducers of non-canonical cell death: a weapon against cancer. Cancers (Basel) 13(2). https:\/\/doi.org\/10.3390\/cancers13020304","DOI":"10.3390\/cancers13020304"},{"key":"2614_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cancergen.2023.07.001","volume":"276\u2013277","author":"LM Marinelli","year":"2023","unstructured":"Marinelli LM, Romain JT, Ehman W, Ortega V, Velagaleti G, Gibbons TF et al (2023) Myeloid\/lymphoid neoplasm with FGFR1 rearrangement presenting with polycythemia vera and T-cell acute lymphoblastic leukemia. Cancer Genet 276\u2013277:43\u201347","journal-title":"Cancer Genet"},{"issue":"36","key":"2614_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303807","volume":"10","author":"J Ren","year":"2023","unstructured":"Ren J, Yu P, Liu S, Li R, Niu X, Chen Y et al (2023) Deubiquitylating enzymes in cancer and immunity. Adv Sci 10(36):e2303807","journal-title":"Adv Sci"},{"key":"2614_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47030211","author":"C Liu","year":"2025","unstructured":"Liu C, Deng Y, Huang L, Nie X, Jiang Y, Zhang X et al (2025) USP5 suppresses ferroptosis in bladder cancer through stabilization of GPX4. Curr Issues Mol Biol. https:\/\/doi.org\/10.3390\/cimb47030211","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"2614_CR57","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12951-022-01605-4","volume":"20","author":"S Waheed","year":"2022","unstructured":"Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J (2022) Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnology 20(1):395","journal-title":"J Nanobiotechnology"},{"key":"2614_CR58","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3762\/bjnano.15.98","volume":"15","author":"AF Lima","year":"2024","unstructured":"Lima AF, Justo GZ, Sousa AA (2024) Realizing active targeting in cancer nanomedicine with ultrasmall nanoparticles. Beilstein J Nanotechnol 15:1208\u20131226","journal-title":"Beilstein J Nanotechnol"},{"issue":"7","key":"2614_CR59","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1172\/JCI45600","volume":"121","author":"M Benezra","year":"2011","unstructured":"Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A et al (2011) Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest 121(7):2768\u20132780","journal-title":"J Clin Invest"},{"issue":"11","key":"2614_CR60","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nnano.2016.164","volume":"11","author":"SE Kim","year":"2016","unstructured":"Kim SE, Zhang L, Ma K, Riegman M, Chen F, Ingold I et al (2016) Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat Nanotechnol 11(11):977\u2013985","journal-title":"Nat Nanotechnol"},{"issue":"11","key":"2614_CR61","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1021\/acs.chemmater.5b01222","volume":"27","author":"K Ma","year":"2015","unstructured":"Ma K, Mendoza C, Hanson M, Werner-Zwanziger U, Zwanziger J, Wiesner U (2015) Control of ultrasmall sub-10 nm ligand-functionalized fluorescent core-shell silica nanoparticle growth in water. Chem Mater 27(11):4119\u20134133","journal-title":"Chem Mater"},{"key":"2614_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686044","volume":"11","author":"L Yang","year":"2021","unstructured":"Yang L, Li C, Qin Y, Zhang G, Zhao B, Wang Z et al (2021) A novel prognostic model based on ferroptosis-related gene signature for bladder cancer. Front Oncol 11:686044","journal-title":"Front Oncol"},{"issue":"5","key":"2614_CR63","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2174\/1874467216666221017122105","volume":"16","author":"M Talebi","year":"2023","unstructured":"Talebi M, Farkhondeh T, Harifi-Mood MS, Talebi M, Samarghandian S (2023) Mechanistic features and therapeutic implications related to the miRNAs and Wnt signaling regulatory in breast cancer. Curr Mol Pharmacol 16(5):530\u2013541","journal-title":"Curr Mol Pharmacol"},{"key":"2614_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020635","author":"L Perera","year":"2025","unstructured":"Perera L, Brown SM, Silver BB, Tokar EJ, Sinha BK (2025) Ferroptosis inducers erastin and RSL3 enhance adriamycin and topotecan sensitivity in ABCB1\/ABCG2-expressing tumor cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26020635","journal-title":"Int J Mol Sci"},{"key":"2614_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122643","author":"F Zhao","year":"2020","unstructured":"Zhao F, Vakhrusheva O, Markowitsch SD, Slade KS, Tsaur I, Cinatl J et al (2020) Artesunate impairs growth in cisplatin-resistant bladder cancer cells by cell cycle arrest, apoptosis and autophagy induction. Cells. https:\/\/doi.org\/10.3390\/cells9122643","journal-title":"Cells"},{"issue":"1","key":"2614_CR66","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1038\/s41598-022-12712-5","volume":"12","author":"X Cheng","year":"2022","unstructured":"Cheng X, Wang Y, Li Y, Liu W (2022) Quantification of ferroptosis pattern in bladder carcinoma and its significance on immunotherapy. Sci Rep 12(1):9066","journal-title":"Sci Rep"},{"key":"2614_CR67","doi-asserted-by":"publisher","unstructured":"Lee J, Roh J-L (2023) Targeting iron-sulfur clusters in cancer: opportunities and challenges for ferroptosis-based therapy. Cancers (Basel) 15(10). https:\/\/doi.org\/10.3390\/cancers15102694","DOI":"10.3390\/cancers15102694"},{"key":"2614_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1374182","volume":"15","author":"Q Liang","year":"2024","unstructured":"Liang Q, Wang Y, Li Y, Wang J, Liu C, Li Y (2024) Ferroptosis: emerging roles in lung cancer and potential implications in biological compounds. Front Pharmacol 15:1374182","journal-title":"Front Pharmacol"},{"issue":"5","key":"2614_CR69","doi-asserted-by":"publisher","first-page":"340","DOI":"10.52547\/ibj.3676","volume":"26","author":"D Doroud","year":"2022","unstructured":"Doroud D, Hozouri H (2022) Role of intravesical BCG as a therapeutic vaccine for treatment of bladder carcinoma. Iran Biomed J 26(5):340\u2013349","journal-title":"Iran Biomed J"},{"key":"2614_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1004148","volume":"12","author":"C Ma","year":"2022","unstructured":"Ma C, Wu X, Zhang X, Liu X, Deng G (2022) Heme oxygenase-1 modulates ferroptosis by fine-tuning levels of intracellular iron and reactive oxygen species of macrophages in response to Bacillus Calmette-Guerin infection. Front Cell Infect Microbiol 12:1004148","journal-title":"Front Cell Infect Microbiol"},{"key":"2614_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683951","volume":"11","author":"Y Du","year":"2021","unstructured":"Du Y, Miao W, Jiang X, Cao J, Wang B, Wang Y et al (2021) The epithelial to mesenchymal transition related gene calumenin is an adverse prognostic factor of bladder cancer correlated with tumor microenvironment remodeling, gene mutation, and ferroptosis. Front Oncol 11:683951","journal-title":"Front Oncol"},{"issue":"1","key":"2614_CR72","doi-asserted-by":"publisher","first-page":"e1630","DOI":"10.1002\/wsbm.1630","volume":"16","author":"P Rispoli","year":"2023","unstructured":"Rispoli P, Scandiuzzi Piovesan T, Decorti G, Stocco G, Lucaf\u00f2 M (2023) iPSCs as a groundbreaking tool for the study of adverse drug reactions: a new avenue for personalized therapy. WIREs Mechanisms of Disease 16(1):e1630","journal-title":"WIREs Mechanisms of Disease"},{"issue":"1","key":"2614_CR73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13287-023-03239-1","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang X, Huang X, Tang X, Zhang M, Li Z et al (2023) Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma. Stem Cell Res Ther 14(1):15","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"2614_CR74","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1016\/j.apsb.2021.03.036","volume":"11","author":"N Kong","year":"2021","unstructured":"Kong N, Chen X, Feng J, Duan T, Liu S, Sun X et al (2021) Baicalin induces ferroptosis in bladder cancer cells by downregulating FTH1. Acta Pharm Sin B 11(12):4045\u20134054","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"2614_CR75","doi-asserted-by":"publisher","first-page":"32197","DOI":"10.1038\/s41598-025-12187-0","volume":"15","author":"L Zhao","year":"2025","unstructured":"Zhao L, Xu Z, Ren L, Zheng S, Gao J, Che H et al (2025) Investigating the relationship between peripheral blood transferrin receptor protein and tumor cell ferroptosis, invasion, and metastasis in bladder cancer. Sci Rep 15(1):32197","journal-title":"Sci Rep"},{"key":"2614_CR76","doi-asserted-by":"publisher","first-page":"675651","DOI":"10.3389\/fmolb.2021.675651","volume":"8","author":"J Liu","year":"2021","unstructured":"Liu J, Ma H, Meng L, Liu X, Lv Z, Zhang Y et al (2021) Construction and external validation of a ferroptosis-related gene signature of predictive value for the overall survival in bladder cancer. Front Mol Biosci 8:675651","journal-title":"Front Mol Biosci"},{"issue":"3","key":"2614_CR77","doi-asserted-by":"publisher","first-page":"251","DOI":"10.23736\/S0393-2249.20.03680-2","volume":"72","author":"D Feng","year":"2020","unstructured":"Feng D, Li A, Hu X, Lin T, Tang Y, Han P (2020) Comparative effectiveness of open, laparoscopic and robot-assisted radical cystectomy for bladder cancer: a systematic review and network meta-analysis. Minerva Urol Nefrol 72(3):251\u2013264","journal-title":"Minerva Urol Nefrol"},{"key":"2614_CR78","unstructured":"ClinicalTrials.gov. Enfortumab Vedotin and Pembrolizumab vs. chemotherapy alone in untreated locally advanced or metastatic urothelial cancer. NCT04223856. Available from:  https:\/\/clinicaltrials.gov\/study\/NCT04223856. Accessed 19 Sept 2025"},{"key":"2614_CR79","unstructured":"ClinicalTrials.gov. Enfortumab Vedotin and Pembrolizumab in people with bladder cancer [cited 2025 Sep 19]. NCT05239624. Available from:  https:\/\/clinicaltrials.gov\/study\/NCT05239624"},{"key":"2614_CR80","unstructured":"ClinicalTrials.gov. Sorafenib in treating patients with advanced or metastatic cancer of the urinary tract. NCT00112671. Available from:  https:\/\/www.clinicaltrials.gov\/study\/NCT00112671. Accessed 19 Sept 2025"},{"key":"2614_CR81","unstructured":"ClinicalTrials.gov. Sorafenib and radiotherapy in the treatment of invasive bladder cancer with conservative intent [cited 2025 09.19]. NCT00544609. Available from:  https:\/\/clinicaltrials.gov\/study\/NCT00544609"},{"issue":"4","key":"2614_CR82","doi-asserted-by":"publisher","first-page":"679","DOI":"10.32604\/oncologie.2022.025705","volume":"24","author":"C Liu","year":"2022","unstructured":"Liu C, Yang X, Wang Y, Wu K, Li S, Wang G et al (2022) Ferroptosis\u2019s role in genitourinary system cancer. Oncologie 24(4):679\u2013691","journal-title":"Oncologie"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-025-02614-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-025-02614-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-025-02614-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T16:05:27Z","timestamp":1766160327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-025-02614-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2614"],"URL":"https:\/\/doi.org\/10.1007\/s00109-025-02614-0","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}